In Vitro Study Shows Combinatorial Ablative Strategies Yield Improved Destruction of Pancreatic Cancer Cells

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the potential benefit of the combination of heat (hyperthermia) and freezing (cryoablation) based ablation strategies for the targeting of pancreatic cancer. The study, titled Dual Thermal Ablation of Pancreatic Cancer Cells as an Improved Combinatorial Treatment Strategy, published as an open access article in the journal Liver and Pancreatic Sciences, was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details the impact of treating pancreatic cancer cells using two ablative strategies, cryo and hyperthermic ablation, used clinically to treat pancreatic as well as other cancers. One arm of the study investigated the impact of the combined application of these ablative treatments strategies on pancreatic cancer in an in vitro cell model. The data show that the combination of exposing cancer cells to heat based ablation followed by freezing results in increased cell death compared to when either is applied as a single exposure (mono) therapy. Commenting on the article, Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) stated “this study demonstrates that ablative therapies provide for an effective means of destroying pancreatic cancer cells. These initial findings from this in vitro suggest that further investigation into the use of a dual thermal ablation regime for treating pancreatic cancer is warranted.”

This study was conducted as part of CPSI’s ongoing research and technology development program focused on the development of a next generation cryoablation device (FrostBite™) and approach for the treatment of pancreatic cancer. The initial development efforts behind FrostBite™ and the DTA study have been supported, in part, by a Phase I and II SBIR grant awarded to CPSI by the National Cancer Institute. Ongoing efforts at CPSI continue to build upon this success and are focusing on further development, optimization and testing of FrostBite™ for the treatment of pancreatic cancer as well as other gastroenterological (GI) based cancers. With development underway, CPSI is poised to embark down the commercialization path. To this end, Dr. John M. Baust commented “We are actively seeking investors and partners to join our team to bring this potentially lifesaving technology platform to the market.” To enable this, a start-up company (GI Cryo, Inc.) has been formed focused in the GI area to commercialize FrostBite™ and other related technologies.

The open access article, initially published online November 30th , is timely in view of the recent increased interest in use of cryoablation for the treatment of cancer and can be accessed free of charge via the Liver and Pancreatic Science website at

Click Here to read the full Press Release: Combinatorial Ablative Strategies Yield Improved Destruction of Pancreatic Cancer Cells

More information on FrostBite™ or any of CPSI’s other technologies is available on CPSI Biotech’s website

Chapter in “Multiscale Technologies for Cryomedicine” details the technologies and approaches used for cryoablation and features CPSI’s patented next generation Supercritical Nitrogen cryoablation device

OWEGO, NY – CPSI Biotech announced today the publication of the new medical text, Multiscale Technologies for Cryomedicine – Implementation form Nano to Macroscale, which includes a chapter authored by CPSI scientists. The chapter titled “Enhanced Cryoablative Methodologies” focuses on the various technologies, approaches and mechanisms involved in the use of cryoablation. In addition to technologies used today clinically, the chapter highlights several next generation technologies, including CPSI’s supercritical nitrogen system (SCN), which has shown promise in advancing the application of cryoablation for the treatment of numerous cancers and cardiac arrhythmias.

The text, published by World Scientific Publishing Co, was co-edited by Dr. Xiaoming He (Ohio State University) and Dr. John Bischof (University of Minnesota) and is a compilation of works by renowned researchers working in the field of cryomedicine covering topic areas ranging from cryoablation of cancer to various aspects of cell cryopreservation. When asked about the book, Dr. John M. Baust (President, CPSI Biotech and lead author on CPSI’s contribution) stated “Drs. He and Bischof should be congratulated for a superb job assembling this text. The book covers a broad array of hot topic areas in the field of Cryomedicine and should be highly valuable to a wide readership including clinicians and researchers alike.”

Multiscale Technologies for Cryomedicine, initially published online as an e-book in July, is timely in view of the growing interest in use of cryoablation for the treatment of cancer and can be accessed via the World Scientific Publishing Co website at

Click here to read the full press release: CPSI’s SCN Cryoablation System Highlighted in New Medical Text

View other CPSI Biotech news and recent patent announcements

Article published in BioProcessing Journal details how CPSI Biotech’s novel SmartThaw™ dry thawing device could revolutionize frozen sample thawing

OWEGO, NY – A peer-reviewed research article detailing the development of CPSI’s SmartThaw™ device was published in this month’s issue of BioProcessing Journal (Volume 15, Number 1; pages 30-41).  The manuscript, titled Development and Assessment of a Novel Device for the Controlled Dry Thawing of Cryopreserved Cell Products, focuses on comparative evaluations between SmartThaw™ and water bath thawing (the gold standard) using human mesenchymal stem cell (hMSC) and prostate cancer (PC-3) cell cultures and demonstrates the improvement in sample processing and quality obtained using SmartThaw™.

Click here to read the full press release: SmartThaw™ Offers a New Standard in Thawing of Cryopreserved Products

View other CPSI Biotech news and recent patent announcements